104 related articles for article (PubMed ID: 38754056)
1. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract][Full Text] [Related]
2. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
3. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
4. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Mutch D; Voulgari A; Chen XM; Bradley WH; Oaknin A; Perez Fidalgo JA; Montosa FG; Herraez AC; Holloway RW; Powell MA; Nowicka M; Schaefer G; Merchant M; Yan Y
Cancer; 2024 Jun; 130(11):1940-1951. PubMed ID: 38288862
[TBL] [Abstract][Full Text] [Related]
5. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM; Krivak TC; Wright GS; Hamilton E; Fleming EL; Belotte J; Keeton EK; Wang P; Gupta D; Clements A; Gray HJ; Konecny GE; Moore RG; Richardson DL
Gynecol Oncol; 2022 Aug; 166(2):219-229. PubMed ID: 35690498
[TBL] [Abstract][Full Text] [Related]
8. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Yap TA; Bessudo A; Hamilton E; Sachdev J; Patel MR; Rodon J; Evilevitch L; Duncan M; Guo W; Kumar S; Lu S; Dezube BJ; Gabrail N
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35332062
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
11. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
[TBL] [Abstract][Full Text] [Related]
14. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
[TBL] [Abstract][Full Text] [Related]
15. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
[TBL] [Abstract][Full Text] [Related]
16. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos PA; Waggoner S; Vidal GA; Mita M; Moroney JW; Holloway R; Van Le L; Sachdev JC; Chapman-Davis E; Colon-Otero G; Penson RT; Matulonis UA; Kim YB; Moore KN; Swisher EM; Färkkilä A; D'Andrea A; Stringer-Reasor E; Wang J; Buerstatte N; Arora S; Graham JR; Bobilev D; Dezube BJ; Munster P
JAMA Oncol; 2019 Aug; 5(8):1141-1149. PubMed ID: 31194228
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
18. Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.
Passiglia F; Righi L; Bironzo P; Listì A; Farinea G; Capelletto E; Novello S; Merlini A; Scagliotti GV
Clin Cancer Res; 2024 Mar; 30(5):959-964. PubMed ID: 38109438
[TBL] [Abstract][Full Text] [Related]
19. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
20. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
